Azzad Asset Management Inc /Adv Sage Therapeutics, Inc. Transaction History

Azzad Asset Management Inc /Adv

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 01, 2024	SELL	$26.15 - $77.24 $111,032 - $327,961	-4,246 Closed	0 $0
Q3 2019 Apr 01, 2024	BUY	$140.29 - $189.96 $173,819 - $235,360	1,239 Added 41.2%	4,246 $386 Million
Q1 2019 Apr 01, 2024	BUY	$89.33 - $163.65 $268,615 - $492,095	3,007 New	3,007 $478 Million
Q4 2018 Apr 01, 2024	SELL	$81.94 - $139.71 $164,371 - $280,258	-2,006 Closed	0 $0
Q3 2018 Apr 01, 2024	BUY	$138.11 - $169.04 $277,048 - $339,094	2,006 New	2,006 $283 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.